Purchase of rights to use nanofluidics with nanoplasmonik for maximum miniaturization and multi-sample analysis
November 28, 2016
The background to the invention started more than four years ago, when Insplorion’s founder Christoph Langhammer’s knowledge in nanoplasmonics combined with Fredrik Westerlund's knowledge in nanofluidics. The new technology is expected to solve the problem of obtaining very small concentrations of molecules of interest to the measuring point where the detection takes place, so that the analysis can be done in a reasonable time. The solution, still in early technical development, is considered to have great potential for detecting everything from biomarkers in blood samples at low concentrations to more general medical and biosensor development.
Protecting this technical solution is in line with the strategy Insplorion have for future product development in both business areas; Instruments and Sensor Systems. In both areas is it important to miniaturize and measure at several points simultaneously. The possibility to ensure that target molecules through nano channels quickly find their way to the detection site is also deemed as of great importance for future application areas.
"We are pleased that we are strengthening our protection for future products in both our business areas with this work. The inventors are compensated in two steps, a smaller portion for the patent application and a future royalty payment based on future sales of products based on the patent. In this way, the compensation is fair and everyone wants to continue to contribute to the commercialization even in this early development phase of the project." comments Patrik Dahlqvist, CEO of Insplorion.
Questions are answered by:
Patrik Dahlqvist, CEO Insplorion AB, +46 723 62 32 61 or email@example.com
Send us an enquiry.
We’ll get back to you as soon as we can.